Mark W. Womack

As the new CEO and managing director, Womack provides leadership to drive an aggressive growth and profitability strategy for Stelis in its business streams that include global contract development and manufacturing organization (CDMO) services and the development of the company's biosimilars pipeline, and integrated vaccines play. He is responsible for the company's overall strategy and provides the necessary direction and leadership to R&D, manufacturing, business development, and commercial operations.

Before joining Stelis, Womack was the chief business officer for AGC Biologics. In his role at AGC, he led the organization to nearly a three-times increase in new sales in just two years and drove the acquisition of most of the world's top large pharma companies into their portfolio. Before that, leveraging his management consulting background, Mark led the global integration of three former CDMOs that were merged to create AGC Biologics.

Womack has served over 25 years as a management consulting industry leader and C-level client advisor, leading large-scale business transformations and guiding many of the world's renowned companies to achieve record highs in revenue and profit. During this time, he served as the Chief Operating Officer for two international management consulting companies.